Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,201–3,300 of 4,628
Idiopathic pulmonary fibrosis in East Asian
Sun, C., Sun, Y., Shen, H., Yang, C., & Xu, S. (2017) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01014 · Cited by 3
Biomarkers for Staging and Evaluating the Therapy for Idiopathic Pulmonary Fibrosis
Hara, Y., Shinkai, M., & Rubin, B. K. (2015) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000111 · Cited by 4
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis
Nathan, S. D., & Martínez, F. J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000407 · Cited by 3
Behr, J., Günther, A., Kreuter, M., Koschel, D., Prasse, A., Pfeifer, M. A., & Costabel, U. (2017) · Pneumologie · doi:10.1055/s-0043-109856 · Cited by 6
Self-citationLung Transplantation in Interstitial Lung Disease
Kim, C., CORDOVA, F. C., & Toyoda, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_5 · Cited by 3
M24 Do antifibrotics impact on lung transplantation outcomes in idiopathic pulmonary fibrosis?
Huong, Y., Dhunnoo, V., Leonard, C. T., Venkateswaran, R., & Chaudhuri, N. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210983.446 · Cited by 3
Pulmonary Rehabilitation in Restrictive Thoracic Disorders
Holland, A. E., & Ambrosino, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-65888-9_28 · Cited by 4
Baldi, B. G. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000060003 · Cited by 5
ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs)
Mishra, S., Shah, M. I., Sarkar, M. S., Asati, N., & Rout, C. (2018) · Database · doi:10.1093/database/bay053 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2017) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2017.17219 · Cited by 3
Hollin, I. L., Dimmock, A. E. F., Bridges, J. F. P., Danoff, S. K., & Bascom, R. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s201632 · Cited by 4
Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis
Kang, H.-R., & Choi, S. M. (2020) · Journal of Korean Medical Association · doi:10.5124/jkma.2020.63.3.159 · Cited by 3
An update on recent randomized clinical trials in systemic sclerosis
Boleto, G., Avouac, J., & Allanore, Y. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105184 · Cited by 3
Ten Commandments for Randomized Trials of Pharmacological Therapy for COPD and Other Lung Diseases
Suissa, S. (2021) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2021.1968816 · Cited by 5
Pulmonary Fibrosis in Sarcoidosis
Carmona, E. M., Francesqui, J., & Kalra, S. (2021) · Barcelona Respiratory Network · doi:10.23866/brnrev:2021-m0066 · Cited by 4
Interstitial lung disease on the acute take for the non-respiratory physician
Yioe, V., Phillips, G., & Spencer, L. G. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0694 · Cited by 3
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.019 · Cited by 4
Self-citationOutpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
Sayah, D. M., & Pilewski, J. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.002 · Cited by 4
(2016) · Australian Prescriber · doi:10.18773/austprescr.2016.031 · Cited by 3
Westerink, L., Nicolai, J. L. J., Postma, M. J., van Boven, J. F. M., & Boersma, C. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00354-2 · Cited by 6
Guo, R., Zhou, Y., Lin, F., Li, M., Tan, C., & Xu, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981604 · Cited by 4
“Idiopathic pulmonary fibrosis (IPF) is themost common form of chronic interstitial lung disease and accounts for 25%–30% of interstitial lung disease (Richeldi et al., 2014; Poletti et al., 2018).”
BackgroundChest CT in covid-19 pneumonia's follow-up: A 30 patients case series
Ramdani, H., Benelhosni, K., Billah, N. M., & Nassar, I. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104835 · Cited by 6
“Anti-fibrotic drugs utilized in chronic lung fibrosis are reviewed, specifically nintedanib [55], an inhibitor of tyrosine-kinase that retards advancement in IPF [56].”
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01476-3 · Cited by 7
Suzuki, A., Kamio, K., Takeno, M., Terasaki, Y., Taniuchi, N., Sato, J., Nishijima, N., Saito, Y., Seike, M., Gemma, A., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231158279 · Cited by 4
Self-citationNanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis
Kanvinde, S., Deodhar, S., Kulkarni, T. A., & Jogdeo, C. M. (2023) · BioTech · doi:10.3390/biotech12020034 · Cited by 3
“In INPULSIS-1 and -2 trials, it showed reduced decline in FVC in nintedanib-treated patients as compared to placebo arm [14].”
MethodTreatment of Idiopathic Pulmonary Fibrosis
Nathan, S. D., Brown, A. W., & King, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32794-5_7 · Cited by 4
Yamaguchi, M., Seto, T., Furuya, A., Edagawa, M., Shimamatsu, S., Toyozawa, R., Toyokawa, G., Nosaki, K., Hirai, F., Takenoyama, M., et al. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.08.011 · Cited by 2
Systematic review of content and quality of idiopathic pulmonary fibrosis review articles
Milne, K. M., Chan, C., Fisher, J. H., de Boer, K., & Ryerson, C. J. (2018) · ERJ Open Research · doi:10.1183/23120541.00156-2018 · Cited by 3
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Mohning, M. P., Swigris, J. J., & Olson, A. L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_2 · Cited by 2
Blood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality?
Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201606-1128ed · Cited by 3
Gokey, J. J., Snowball, J. M., Green, J., Waltamath, M., Spinney, J. J., Black, K. E., Hariri, L. P., Xu, Y. J., & Perl, A. T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.080994 · Cited by 3
Interstitial Pneumonia With Autoimmune Features
Graney, B. A., & Fischer, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11360-1 · Cited by 5
Hypoxia-inducible factor-2 (HIF2) regulates alveolar regeneration after repetitive injuryPreprint
McCall, A. S., Tanjore, H., Burman, A., Sherrill, T. P., Chapman, M., Calvi, C. L., Camarata, J. E., Hunt, R. P., Nichols, D. S., Banovich, N. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.17.557477 · Cited by 3
Liu, Y., Habibie, H., Borghuis, T., Liu, G., Hansbro, P. M., Melgert, B. N., & Burgess, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.05.626371 · Cited by 2
Zhang, S., Zhou, M., Shao, C., Zhao, Y., Liu, M., Ni, L., Bao, Z., Zhang, Q., Zhang, T., Luo, Q., et al. (2024) · eLife · doi:10.7554/elife.102451 · Cited by 4
“Furthermore, patients with IPF may discontinue Nintedanib and Pirfenidone due to adverse events such as nausea and diarrhea ( Vancheri et al., 2018 ; Flaherty et al., 2018 ; Milger et al., 2015 ; Richeldi et al., 2014 ; Noble et al., 2011 ).”
Hoffman, E. T., Barboza, W. R., Rodriguez, L. R., Dherwani, R., Tomer, Y., Murthy, A., Bennett, A., Nottingham, A. N., Babu, A., Chavez, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599351 · Cited by 6
Ziehr, D. R., Li, F., Parnell, K. M., Krah, N. M., Leahy, K. J., Guillermier, C., Gao, C., Prell, S. A., Vigder, N., Poli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ads2673 · Cited by 17
Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
Ignatova, G. L., Blinova, E. V., Belsner, M. S., & Korotkaya, M. A. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.9.201962 · Cited by 2
Kokubu, H., Takeuchi, S., Tozawa, T., Hisada, S., Yamada, Y., Itoh, Y., & Kodera, M. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14611 · Cited by 2
Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease
LIU, J., WANG, F., YUAN, B., & Luo, F. (2023) · Biocell · doi:10.32604/biocell.2023.026148 · Cited by 3
Comparing the Utilization of Antifibrotic Medications Based on Income Level
Dempsey, T. M., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & LIMPER, A. H. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.07.4215 · Cited by 2
Moore, Z., Huang, X., Lobaugh, S. M., Zhang, Z., Wong, P., Geyer, A. I., Pagano, A., Rudin, C. M., Jones, D. R., Gomez, D. R., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110320 · Cited by 2
Sun, S., Wang, Y., & Feng, J. (2025) · Hereditas · doi:10.1186/s41065-025-00401-y · Cited by 3
Luo, Y., Assassi, S., Mayes, M. D., Frech, T., Steen, V. D., Richardson, C., Chung, L. S., Sandorfi, N., VanBuren, J. M., Harding, M. L., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202410-1045rl · Cited by 2
Çilli, A., Üzer, F., Cömert, S. Ş., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108098 · Cited by 2
Enomoto, T., Takeda, Y., Shirai, Y., Hasegawa, T., Zhao, F., Lunding, H. B., Pohl, M., Edahiro, R., Shichino, S., Kawasaki, T., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03237-2 · Cited by 2
Self-citationAn Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis
Lian, X., Liu, B., Li, D., Wang, X., Long, C., Feng, X., Liao, Q., & Rong, M. (2025) · Toxins · doi:10.3390/toxins17050213 · Cited by 2
“Currently, the two main drugs for IPF treatment, pirfenidone and nintedanib, can only delay the progression of the disease and do not provide a complete cure [16]. addition, these drugs have undesirable side effects including nausea, vomiting severe diarrhea [17,18].”
Idiopathic pleuroparenchymal fibroelastosis: diagnosis and management
Ishii, H., Kinoshita, Y., Hamada, N., Fujita, M., & Kushima, H. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2499651 · Cited by 3
LncRNA SYISL promotes fibroblast myofibroblast transition via miR-23a-mediated TRIOBP regulation
Xia, C., Cheng, L. C., Zhao, W., Chang, A., Wang, Z., Liu, H., Pan, X., Li, W., Sakamoto, K., Li, Z., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05729-2 · Cited by 8
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 7
Li, F., Vigder, N., Ziehr, D. R., Kamiya, M., Nguyen, H. N., Faustino, D. E. F., Khalil, A. H., Lam, H. C., Steinhauser, M. L., Kim, E. Y., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.199449 · Cited by 6
Miceli, V., Callari, A., Calzolari, E., Castelbuono, S., Claudia, C., Lanzarone, N., Martino, L., Conaldi, P. G., Pinzani, M., & Vitulo, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-12952-1 · Cited by 3
Srivali, N., Giacomi, F. D., Moua, T., & Ryu, J. H. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.08.002 · Cited by 4
Dimić-Janjić, S., Stjepanović, M., Belić, S., Vukosavljević, D., Milivojević, I., Trboljevac, N., Nikolić, N., Stamenić, S., Stojanović, M., Stosic, K., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15172121 · Cited by 3
“The INPULSIS study, which demonstrated the benefit of nintedanib in treating IPF, also showed that patients with probable UIP had a higher median survival and a more extended period before their first exacerbation [27].”
Nick, P. L.-K., Studnicka, M., Gregor, J., Ovesná, P., Vašáková, M., Simmons, W., Li, Y., Strek, M. E., Li, P., Snyder, L. D., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00402-2025 · Cited by 3
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.003 · Cited by 4
Trapman, L., Dijksman, L. M., Grutters, J. C., Teunissen, S. C. C. M., & de Graaf, E. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.09.007 · Cited by 3
Treatable traits in interstitial lung disease: opportunities and challenges
Khor, Y. H., Podolanczuk, A. J., Renzoni, E. A., McDonald, V. M., Cottin, V., Holland, A. E., Inoue, Y., Russell, A., Song, J. W., Wijsenbeek, M. S., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108353 · Cited by 4
Self-citationTsubouchi, K., Hirose, M., Takei, R., Fujisawa, T., Tobino, K., Ichiyasu, H., Izumi, S., Sakamoto, N., Asami‐Noyama, M., Nishiyama, O., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00697-2025 · Cited by 4
Andugulapati, S. B., Kambhampati, V., & Kumar, H. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00322 · Cited by 2
Bolger, G. B. (2025) · Life · doi:10.3390/life15101600 · Cited by 6
Shah, A., Lopez, E. K., Geller, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102522 · Cited by 2
“Antifibrotics such as nintedanib and pirfenidone have been considered, given that they have shown survival benefits in patients with isolated PF [9,10].”
InfluentialNishimura, H., Kawano, H., Sato, S., Imakura, T., Yamashita, Y., Murakami, K., Haji, K., Bando, H., Naito, N., Kagawa, K., et al. (2025) · The Journal of Medical Investigation · doi:10.2152/jmi.72.298 · Cited by 2
Arai, T., Hirose, M., Kagawa, T., Takeuchi, N., Kobayashi, T., Inoue, Y., & Matsuda, Y. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227914 · Cited by 3
“…is a tyrosine kinase inhibitor (TKI) that works by inhibiting signal transduction through the platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) receptors [2], and has been used in the management of patients with IPF and PPF [1,3,4].”
Self-citationHuang, X., Zhang, Y., Yan, X., Huang, Q., Chen, M., Jiang, C., Wang, Z., Sun, D., Li, Y., Ding, J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114427 · Cited by 3
The role of epigenetic regulation in idiopathic pulmonary fibrosis
Li, R. M., Stentenbach, M., Tan, D. B. A., Ludewick, H. P., Walters, E. H., Clynick, B., & Moodley, Y. P. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2025 · Cited by 3
Classification of interstitial pneumonias: ready for the future or stuck in the past?
Kolb, M. R. J., Cottin, V., & Crestani, B. (2025) · European Respiratory Journal · doi:10.1183/13993003.01845-2025 · Cited by 2
Self-citationSnoeck, H. (2025) · European Respiratory Journal · doi:10.1183/13993003.02083-2025 · Cited by 6
Trapman, L., Dijksman, L. M., Grutters, J. C., Teunissen, S. C. C. M., & de Graaf, E. (2025) · PLoS ONE · doi:10.1371/journal.pone.0338624 · Cited by 2
“While survival without medication typically ranges from three to five years, the use of antifibrotics has been linked to an extension of this timeframe, by slowing the decline in Forced Vital Capacity of the lung function by 50% [4,5].”
Network-guided discovery of Zeqi Decoction as a PPARγ-targeted therapy for pulmonary fibrosis
Qiu, Y., Xin, G., Wei, Z., Wang, T., Zhang, S., Zhou, Q., Li, L., Sun, D., Xu, X. S., Wen, A., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157717 · Cited by 3
Fibrotic Chronic Eosinophilic Pneumonia Treated with an Anti-IL-5 Monoclonal Antibody: A Case Report
Semenzato, U., Previtero, D., Castelli, G., et al. (2025) · Biologics · doi:10.3390/biologics5030023 · Cited by 2
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-34071-7 · Cited by 3
Shi, J., Miao, H., Li, C., & Tong, Z. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2611906 · Cited by 2
Min, J., Zhang, Y., Yang, J., Liu, S., Wang, Q., Tang, X., Yuan, F., Xia, Z., Li, X., Peng, H., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-04007-4 · Cited by 4
The role of free‐fatty acid receptors FFA1 and FFA4 in organ fibrosis
Karmokar, P. F., & Moniri, N. H. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70334 · Cited by 4
Kijlertsuphasri, S., Petnak, T., & Moua, T. (2026) · Thorax · doi:10.1136/thorax-2025-223803 · Cited by 3
Reframing fibrosis as a barrier to regeneration and gene delivery in muscular diseases
Kılıç, H. B., & Kocaefe, Ç. (2026) · FEBS Journal · doi:10.1111/febs.70427 · Cited by 3
Maddali, M. V., Pugashetti, J. V., Pienkos, S. M., Moore, A. R., Konkol, S., Kim, J. S., Ma, S.-F., Newton, C. A., Garcia, C. K., Adegunsoye, A., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag006 · Cited by 3
Liang, H., Lang, Q., Liang, Z., & Sun, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s568106 · Cited by 3
Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
Zanini, U., Franco, G., Pirotta, C., Passeri, E., Mazzotta, S. M., Ferrara, G., Mura, M., Faverio, P., & Luppi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762243 · Cited by 2
“The antifibrotic agent nintedanib, as demonstrated in the INPULSIS and INBUILD trials, has been approved for the treatment of IPF and other progressive fibrosing interstitial lung diseases (PF-ILDs) (70, 71).”
Yang, Q., Xie, C., Luo, Z., Huang, W., Zhang, Z., Ren, K., Xu, X., HE, H., He, M., & Yin, L. (2026) · Redox Report · doi:10.1080/13510002.2026.2632434 · Cited by 4
Standalone prognostication of idiopathic pulmonary fibrosis using attention-based deep learning
Lee, J. H., Chae, K. J., Lee, H. S., Park, J., Choi, S. M., Goo, J. M., & Kim, H. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag098 · Cited by 3
Zheng, C., Ding, W., Sun, Y., Wang, Y., & Zhang, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s576680 · Cited by 3
Nagre, N. N., Srinivas, B., Richards, N., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104117 · Cited by 2
Zheng, J., Du, H., Ni, H., Liu, M., Yu, Z., Dong, Y., & Guo, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116511 · Cited by 2
RetractedKaburaki, S., Tanaka, T., Kamio, K., Tanaka, Y., Taniuchi, N., Kasahara, K., & Seike, M. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag069 · Cited by 2
Poletti, V. E., Ryerson, C. J., & Piciucchi, S. (2026) · European Respiratory Journal · doi:10.1183/13993003.01903-2025 · Cited by 2
Wang, Y., Peng, X., Chen, J., Zhang, Y., Zhang, T., Zhang, J., Fan, J., Zheng, H., Liu, Q., Song, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.202515581 · Cited by 3
Solomon, J. J., Dieudé, P., Matson, S. M., Lee, J. S., Rojas‐Serrano, J., Sebastiani, M., Gonzalez, A., Demoruelle, M. K., Hoffman‐Vold, A., Kam, M. L. W., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00094-9 · Cited by 12
Self-citationProgressive pulmonary fibrosis: a state-of-the-art review
Cottin, V., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., Lynch, D. A., Oldham, J. M., Valenzuela, C., Wijsenbeek, M. S., & Wells, A. U. (2026) · European Respiratory Journal · doi:10.1183/13993003.01557-2025 · Cited by 4
Self-citationFricke, U., Hein, L., & Schwabe, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_3 · Cited by 1
Systemische Sklerose: Was ist gesichert in der Therapie?
Becker, M. O. (2016) · Der Internist · doi:10.1007/s00108-016-0148-1 · Cited by 2
Toward understanding patient experience in idiopathic pulmonary fibrosis
Danoff, S. K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02202-2016 · Cited by 2
Moon, R., Barker, E., Agnew, S., Sutcliffe, J., Kwok, A., & Spencer, L. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210983.447 · Cited by 1
Ambulatory oxygen and quality of life in interstitial lung disease
Page, D. B., & Thannickal, V. J. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30337-0 · Cited by 2
Planté-Bordeneuve, T., Haouas, H., Vanderheyde, K., & Froidure, A. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1545375 · Cited by 2
“Patients with an IPF presentation are eligible to pirfenidone and nintedanib, two anti-fibrotic agents reducing FVC decrease [22,23], although a recent study has”
BackgroundCase 10-2019: A 69-Year-Old Man with Progressive Dyspnea
Black, K. E., Montesi, S. B., Feneis, J. F., & Mark, E. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmcpc1900143 · Cited by 2
Roudbary, M., Keyvani, H., Mousavi, S. A., Esghaei, M., Roudbarmohammadi, S., Hedayati, N., Salehabadi, G., Falahati, M., & Ashrafi‐Khozani, M. (2019) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid.65758 · Cited by 2
“There is no definite care for IPF therapy and lung transplantation is the only alternative to save a small number of patients from the danger of death (3-6).”
BackgroundWeikert, T., Sommer, G., Tamm, M., Haegler, P., Cyriac, J., Sauter, A. W., Hostettler, K., & Bremerich, J. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.108719 · Cited by 2
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.